Iterum Therapeutics plc Quarterly Income Tax Expense (Benefit) in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Iterum Therapeutics plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2017 to Q3 2024.
  • Iterum Therapeutics plc Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $136K, a 15.5% decline year-over-year.
  • Iterum Therapeutics plc Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $357K, a 37.6% decline year-over-year.
  • Iterum Therapeutics plc annual Income Tax Expense (Benefit) for 2023 was $613K, a 104% increase from 2022.
  • Iterum Therapeutics plc annual Income Tax Expense (Benefit) for 2022 was $301K, a 57.3% decline from 2021.
  • Iterum Therapeutics plc annual Income Tax Expense (Benefit) for 2021 was $705K, a 5.11% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $357K $136K -$25K -15.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $382K $31K -$156K -83.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $538K $48K -$75K -61% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $613K $142K +$41K +40.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $572K $161K +$731K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$159K $187K -$156K -45.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$3K $123K -$304K -71.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $301K $101K -$70K -40.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $371K -$570K -$922K -262% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $1.29M $343K +$221K +181% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $1.07M $427K +$367K +612% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $705K $171K +$147K +613% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-28
Q3 2021 $558K $352K -$68K -16.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $626K $122K -$56K -31.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $682K $60K -$61K -50.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $743K $24K -$25K -51% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-16
Q3 2020 $768K $420K +$316K +304% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $452K $178K +$21K +13.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $431K $121K -$13K -9.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $444K $49K -$157K -76.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-28
Q3 2019 $601K $104K -$5K -4.59% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $606K $157K +$89K +131% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $517K $134K +$45K +50.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $472K $206K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-12
Q3 2018 $109K +$21K +23.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $68K -$10K -12.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $89K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q3 2017 $88K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 $78K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.